Hledat
Zobrazují se záznamy 1-6 z 6
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease
(2022)
Recently, we defined "CML-like" subtype of BCR::ABL1-positive acute lymphoblastic leukemia (ALL), resembling lymphoid blast crisis of chronic myeloid leukemia (CML). Here we retrospectively analyzed prognostic relevance ...
Chimeric JAK2 Kinases Trigger Non-uniform Changes of Cellular Metabolism in BCR-ABL1-like Childhood ALL
(2023)
We studied the impact of JAK2 fusions on metabolic rewiring of leukemic cells; we chose two representatives, themost frequent fusion and a novel previously undescribed fusion, and we showed that JAK2 fusions indeed alter ...
Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia
(2023)
High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, ...
Restored biosynthetic pathways induced by MSCs serve as rescue mechanism in leukemia cells after L-asparaginase therapy
(2023)
L-asparaginase (ASNase), the drug included on the World Health Organization's List of EssentialMedicines, is irreplaceable in the front-line treatment of childhood acute lymphoblastic leukemia(ALL)1 . However, the relapse ...
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study
(2024)
Measurable residual disease (MRD) monitoring in childhood acute myeloid leukemia (AML) is used to assess response to treatment and for early detection of imminent relapse. In childhood AML, MRD is typically evaluated using ...
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
(2023)
We read with a great interest the paper focused on different minimal residual disease (MRD) approaches and its significance in Ph+ acute lymphoblastic leukemia (ALL) patients, authored by Short et al. from the MD Anderson ...